Laboratory of Hematology
The Laboratory of Hematology consists of expertise hematology diagnostics units and research groups.
read moreLaboratory of Hematology
The Laboratory of Hematology consists of expertise hematology diagnostics units and research groups.
Our research focuses on the molecular mechanisms that underlie blood disorders, as well as the development of immunotherapeutic strategies to boost anti-tumor immunity in patients with hematological malignancies. In close collaboration with the Department of Hematology we aim to translate and implement our research developments into diagnostic tests and patient care.
You can contact us for obtaining primary patient and healthy donor material, as well as for laboratory tests and experimental models in the field of cellular immune therapy, molecular hematology and thrombosis & hemostasis. In addition, we house the Flow cytometry technology center.
Units
-
The immune system is a powerful defense mechanism against foreign pathogens, but can also clear altered or damaged cells, such as cancer cells.
read more
Cell Therapy & Immune Therapy
The immune system is a powerful defense mechanism against foreign pathogens, but can also clear altered or damaged cells, such as cancer cells.
For that reason, hematological cancers can be treated with immunotherapy, such as the well-established treatment of allogeneic stem cell transplantation, to induce durable remissions and even cure in patients.
However, persistence and recurrence of malignant disease is often observed in these patients due to inadequate induction and/or reactivation of tumor-reactive immune responses or via to immunosuppressive mechanisms exploited by the tumor cells.
Therefore, potent new and/or improved immunotherapies are required to boost anti-tumor immunity in patients with hematological malignancies. In the translational research program of Dr. Harry Dolstra different immunotherapeutic strategies are investigated.
-
The unit Molecular Hematology Research (MHR) performs research in close collaboration with the unit Molecular Hematology Diagnostics (MHD).
read more
Molecular Hematology
The unit Molecular Hematology Research (MHR) performs research in close collaboration with the unit Molecular Hematology Diagnostics (MHD).
The main goal is to unravel molecular mechanisms that underlie blood disorders, in particular disorders of the myeloid subset of blood cells. These myeloid diseases comprise acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN) and platelet disorders. The close collaboration between MHR and MHD enables the study of primary patient material (cells and DNA), which is of great value.
Every type of cancer arises from a cell that contains defects in its DNA; the defects confer a growth advantage upon the malignant cell, allowing it to outcompete healthy cells. The mutated DNA encodes amongst others transcriptional regulators and epigenetic regulators, proteins that are involved in the control of gene expression. We study mutations in the DNA; evolution of malignant clones; and epigenetic factors, epigenetic profiles, transcription factors and transcriptional regulation in normal and malignant blood cell formation (hematopoiesis). At present, five main topics are studied by several postdocs, PhD students, technicians and master/bachelor students, under the supervision of prof. J.H. Jansen and dr. B.A. van der Reijden.
-
Education & Internships
We are involved in the educational tracks of bachelor and master students at the Radboud University, the Hogeschool Arnhem-Nijmegen and other institutes.
read moreConnected to

Treatment improvement for severe hematological diseases
This program aims to unravel the pathophysiological basis of hematological disease, understand the biological consequences and define possibilities for therapeutic intervention.
read more